Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Uma intervenção de gerenciamento de casos de enfermagem para melhorar os resultados da co-infecção MDR-TB/HIV

14 de setembro de 2026 atualizado por: Johns Hopkins University

The researchers of this study are observing the treatment of multi-drug resistant Mycobacterium tuberculosis (MDR-TB) in South Africa. MDR-TB can not be treated with the usual TB drugs and needs to be treated with special drugs. The patients need to take these drugs for up to two years. Certain hospitals have already agreed to participate in this research project, half of the hospitals will be assigned a nurse case manager and the other half will not. The researchers are studying the benefits of having a nurse case manager to improve treatment response for patients with drug resistant TB. The researchers believe that nurse case management (NCM) in the intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection. To do this, the researchers will review the medical information collected at the hospital as part of the patient's treatment after obtaining the patient's permission.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Mycobacterium tuberculosis (TB) remains the leading cause of death among persons living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) in southern Africa. This syndemic places an overwhelming burden on healthcare workers and the health system. Drug-resistant TB remains a growing threat to public health despite advances in treatment and diagnosis over the past decade. South Africa has the world's highest rate of TB/HIV co-infection and ranks fourth worldwide for both multi-drug resistant (MDR) TB incidence and HIV prevalence. Treatment of MDR-TB, defined as resistance to isoniazid and rifampin, remains challenging and its treatment course complex. Success of second line treatment regimens is considerably less likely than first line treatment with significantly more adverse drug reactions (ADRs). Prospective cohort studies from South Africa report less than 50% treatment success (i.e. cure or completion) and significant differences in patients with and without HIV are noted. Differences in sex and gender as well as age are rarely evaluated. In addition to the management complexity and length of treatment, systems level factors such as access to care and healthcare capacity contribute to poorer treatment outcomes. Insufficient numbers of trained physicians capable and clinically competent to manage the challenges of integrated MDR-TB/HIV care are commonplace. These circumstances place a heavy burden on the most abundant healthcare resource in South Africa, the nurse. Nurses with proficiency in care models for both diseases are essential to improve treatment outcomes. The investigators experience dictates, however, that patients endure lengthy treatment with little assessment, support or guidance from nursing professionals due to a lack of training as well as lack of evidence-based interventions and delineated models of care for MDR-TB patients.

Nurse case management (NCM) models in which a registered nurse facilitates and coordinates treatment plans to ensure that timely, evidence-based care is given improves treatment outcomes. Presently, there is little evidence to describe such models in TB/HIV co-infected patients globally, and specifically less evidence for MDR-TB/HIV in sub-Saharan Africa. Many studies, however, have demonstrated substantial improvements in disease outcomes utilizing nurse case managers. Complex diseases such as heart failure, diabetes, HIV and drug susceptible TB are among these. Substantial gaps remain, however, in the investigators understanding of the impact of such interventions among co-infected patients, the influence of such models among different age groups or the cost-benefit in under resourced settings. Prior studies provide strong evidence that interventions must be multi-faceted and foster system level approaches to improve treatment outcomes (i.e. NCM patient-centered care services coupled with systems level approaches to care coordination). The Chronic Care Model identifies essential elements of a health care system that encourage high-quality chronic disease care in such a systems approach. These elements provide the conceptual model and implementation structure for the proposed NCM plus health systems strengthening (i.e. NCM-plus) intervention, a multi-faceted health systems and patient-centered intervention to improve MDR-TB/HIV treatment outcomes. The proposed 5-year cluster randomized trial, will evaluate the NCM-plus intervention on MDR-TB treatment outcomes in South Africa, the epicenter of the MDR-TB/HIV epidemic.

Primary Aim:

To determine the impact of a NCM model (i.e. NCM-Plus) on MDR-TB outcomes in patients with and without HIV co-infection in South Africa through a cluster randomized trial.

Hypothesis:

Nurse case management (NCM) in intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection.

Secondary Aims:

  1. To conduct sub-group analysis by a) HIV co-infection; b) sex and gender; and c) age
  2. To compare the frequency and time to identification of adverse drug events between intervention and control sites.
  3. To conduct a costing analysis and a cost-effectiveness evaluation of the intervention.

Tipo de estudo

Intervencional

Inscrição (Real)

2844

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Durban, África do Sul
        • King George V Hospital
      • Durban, África do Sul
        • Don McKenzie
      • East London, África do Sul
        • Fort Gray Hospital
      • Hibberdene, África do Sul
        • Dunstan Farrell Hospital
      • Hlabisa, África do Sul
        • Hlabisa Hospital
      • Manguzi, África do Sul
        • Manguzi
      • Mdantsane, África do Sul
        • Nkqubela
      • Newlands West, África do Sul
        • Fosa Hospital
      • Pietermaritzburg, África do Sul
        • Doris Goodwin Hospital
      • Port Alfred, África do Sul
        • Marjorie Parrish Hospital
      • Port Elizabeth, África do Sul
        • Jose Pearson Hospital
      • Port Shepstone, África do Sul
        • Murchison Hospital
      • Umzimkulu, África do Sul
        • St Margaret's MDR-TB Hopsital
    • Durban
      • Westville, Durban, África do Sul, 3629
        • Regus Primary Office
    • KwaZulu-Natal
      • aMatikulu, KwaZulu-Natal, África do Sul
        • Catherine Booth Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

13 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Center (Cluster Level)

    1. MDR-TB Centers in KwaZulu-Natal (KZN) or Eastern Cape (EC), South Africa providing standardized
    2. MDR-TB regimen according to National Department of Health guidelines
    3. Facility has provided MDR-TB care for a minimum of 6 months at study initiation
    4. MDR-TB Centers with facility-based access to anti-retroviral therapy
    5. Facility willingness to participate in the study
  • Individual (Patient Level)

    1. Patients 18 years of age and older, with microbiologically confirmed MDR- TB, admitted to receive inpatient care at a participating hospital who signs informed consent within 7 days of admission.
    2. Patients 13 - 17 years of age, with microbiologically confirmed MDR- TB, who provide consent for study team to contact parent or legal guardian and when patient is willing and parent or legal guardian provides approval for study participation within 7 days of admission.

Exclusion Criteria (Individual Patient Level):

  • Persons who present to the MDR-TB ward who have started MDR-TB treatment prior to admission.
  • Children, less than 13 years of age; only one participating center has an MDR-TB wards for children under 13.
  • Persons who are unable or unwilling to provide informed consent for participation
  • Any patient enrolled in another clinical trial that changes standard MDR- TB or HIV care.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: NCM Plus Intervention

The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.

The NCM will follow the domains of the chronic care model by:

  1. Assuring effective, efficient clinical care and self-management support
  2. Promoting clinical care consistent with scientific evidence and patient preferences
  3. Organizing data to facilitate efficient, effective care
  4. Empowering and preparing patients to manage their health and health-care needs
  5. Mobilizing community resources to meet the needs of patients
Sem intervenção: Standard/Usual Care

Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Patients Who Experience Successful Treatment Outcomes
Prazo: 36 months

Patients who experience successful treatment outcomes

36 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection
Prazo: 36 months

Multivariate Analysis using binomial or Poisson-based GEE models

36 months
Patients Who Experience Successful Treatment Outcomes Based on Sex and Gender
Prazo: 36 months

Multivariate Analysis using binomial or Poisson-based GEE models

36 months
Patients Who Experience Successful Treatment Outcomes Based on Age
Prazo: 36 months

Multivariate Analysis using binomial or Poisson-based GEE models

36 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jason E Farley, PhD, MPH, NP, Johns Hopkins University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de outubro de 2014

Conclusão Primária (Real)

1 de março de 2021

Conclusão do estudo (Real)

1 de dezembro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

29 de abril de 2014

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de maio de 2014

Primeira postagem (Estimado)

2 de maio de 2014

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NA_00078899
  • RO1 104488-01A1 (Número de outro subsídio/financiamento: NIH/NAID)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever